Survival and factors affecting the outcome of synovial sarcoma in children and adolescents single institute experience

Abstract

Introduction: To check the impact of the clinical and pathologic features at diagnosis and treatment given, on the outcome of synovial sarcoma in children and adolescents.
Methods: Retrospective analysis of patients below 18 years old diagnosed by synovial sarcoma and treated at Children Cancer Hospital Egypt 57,357 (CCHE) between July 2007 and December 2016. We reviewed Clinical characteristics, pathological information, treatment modalities and survival data.
Results: We included thirty one patients with median age at diagnosis was 14.8 years. Initial surgical excision was possible in 10 patients (58.8%) while 5 (29.4%) patients underwent surgical excision after response to preoperative chemotherapy. Two patients had unresectable tumor, showed no response to chemotherapy and received radiotherapy as the only local control therapy. Adjuvant radiotherapy only was given in 2 patients and 5 patients received chemotherapy without local radiotherapy and 10 patients received both modalities. The estimated 5-year overall survival and failure free survival rates for the entire group were 84.4% ± 7.2% and 63.8% ± 9.7% respectively, the 5-year OS and FFS were studied in correlation to age of patient, tumor size, different pathological types, site of the lesion and methods of local control. In patients with tumor size below 5 cm when compared to size more than 5 cm with OS was (100%) in comparison to (79.3 ± 9.3) who underwent complete surgical excision either initial or post chemotherapy as it was 66.7% versus 55.6% for those with gross or microscopic residual (p-value =.38). Also, the 3-year failure free survival was 75% versus 56.3% for those smaller than or equal 5 cm and those larger than 5 cm respectively (p-value =.3).
Conclusion: Increasing number of patients to increase sample size to assess tumor size and complete surgical excision as important prognostic factors as in our study, we found them statistically insignificant. Preoperative chemotherapy can help for delayed excision in patients presented initially with unresectable tumors

Keywords

Synovial sarcoma / Tumor size / Surgery

References

[1] Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol. 2003; 15:239-252. https://doi.org/10.1097/00001622-200305000-00011

[2] Carillo R, Rodriguez-Peralto JL, Batsakis JG. Synovial sarcomas of the head and neck. Ann Otol Rhinol Laryngol 1992; 101: 367-370. PMid:1314035. https://doi.org/10.1177/000348949210100415

[3] Stacchiotti S, Brian A. Synovial Sarcoma: Current Con-cepts and Future. Journal of Clinical Oncology. 2018; 36(2): 180-187. https://doi.org/10.1200/JCO.2017.75.1941

[4] Vancheswaran G, Behrang A, Michael JW. Sarcoma of the Head and Neck: A Single Institution Review. Vancheswaran Gopalakrishnan. 2017.

[5] Weiss SGJ, Weis SW, Goldblum JR. Malignant soft tissue tumors of uncertain type. In Enzinger FM, Weiss SW, editors, Enzinger and Weiss’s Soft Tissue Tumors, 4th ed. St. Louis, CV Mosby. 2001; 1483-571.

[6] Siegel HJ, Sessions W, Casillas MJ. Synovial sarcoma: clinicopatho-logic features, treatment, and prognosis. Orthopedics. 2007; 30(12): 1020-5. PMid:18198773.

[7] Brennan B, Stevens M, Kelsey A, et al. Synovial sarcoma in child-hood and adolescence: a retrospectiveseries of 77 patients regis-tered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010; 55: 85-90. https://doi.org/10.1002/pbc.22453

[8] Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a mul-tivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18: 2087-94. PMid:10811674. https://doi.org/10.1200/JCO.2000.18.10.2087

[9] Krieg AH, Hefti F, Speth BM, et al. Synovial sarcomas usually metastasize after > 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol. 2011; 22: 458- 67. PMid:20716627. https://doi.org/10.1093/annonc/mdq394

[10] Kawai A, Woodruff J, Healey JH, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sar-coma. N Engl J Med. 1998; 338: 153-160. PMid:9428816. https://doi.org/10.1056/NEJM199801153380303

[11] Sakabe T, Murata H, Konishi E, et al. Evaluation of clinical outcomes and prognostic factors for synovial sarcoma arising from the extremi-ties. Med Sci Monit. 2008; 14(6): CR305-CR310. PMid:18509273.

[12] Mendenhall WM, Indelicato DJ, Scarborough MT, et al. The man-agement of adult soft tissue sarcomas. Am J Clin Oncol. 2009; 32(4):436-442. PMid:19657238. https://doi.org/10.1097/COC.0b013e318173a54f

[13] Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999; 85(12): 2596-2607. https://doi.org/10.1002/(SICI)1097-0142(19990615)85:12<2596::AID-CNCR16>3.0.CO;2-K

[14] Goodlad JR, Fletcher CD, Smith MA. Surgical resection of primary soft-tissue sarcoma. Incidence of residual tumour in 95 patients need-ing re-excision after local resection. J Bone Joint Surg Br. 1996; 78(4): 658-661. https://doi.org/10.1302/0301-620X.78B4.0780658

[15] Pappo AS, Fontanesi J, Luo X, et al. Synovial sarcoma in children and adolescents: the St Jude Children’s Research Hospital experi-ence. J Clin Oncol. 1994 Nov; 12(11): 2360-2366. PMid:7964951. https://doi.org/10.1200/JCO.1994.12.11.2360

[16] Wisanuyotin T, Radapat K, Sirichativapee W, et al. Prognostic fac-tors and clinical outcomes in synovial sarcoma of the extremities. Asia Pac J Clin Oncol. 2013 Mar; 9(1): 80-5. PMid:22898085. https://doi.org/10.1111/j.1743-7563.2012.01563.x

[17] Singer S, Baldinj EH, Demetri GD, et al. Synovial sarcoma: prognos-tic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996 Apr; 14(4): 1201-8. PMid:8648375. https://doi.org/10.1200/JCO.1996.14.4.1201

[18] Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of child-hood and adolescence: a multicenter, multivariate analysis of out-come. J Clin Oncol. 2003 Apr; 21(8): 1602-11. PMid:12697886. https://doi.org/10.1200/JCO.2003.07.008

[19] Speth BM, Krieg AH, Kaelin A, et al. Synovial sarcoma in patients un-der 20 years of age: a multicenter study with a minimum follow-up of 10 years. J Child Orthop. 2011 Oct; 5(5): 335-342. PMid:23024724. https://doi.org/10.1007/s11832-011-0360-4

[20] Brecht IB, Ferrari A, Int-Veen C, et al. Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant ther-apies. Pediatr Blood Cancer. 2006 Jan; 46(1): 11-7. PMid:16292743. https://doi.org/10.1002/pbc.20502